- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02542007
Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions (RECOVERY)
September 8, 2021 updated by: OrbusNeich
RECOVERY: A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions of Native Coronary Artery
To evaluate the safety, efficacy and deliverability of the Combo bio-engineered sirolimus-eluting stent versus the Nano polymer-free sirolimus- eluting stents in the treatment of patients with de novo stenotic lesions of native coronary artery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, multi-center, open-label, non-inferiority, randomized controlled trial which plans to enroll 436 subjects.
All subjects enrolled will be randomly assigned to the test group (n=218) and the control group (n=218).
Subjects in the test group and the control group will receive Combo stents and Nano stents respectively.
Study Type
Interventional
Enrollment (Actual)
440
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Beijing Chao Yang Hospital
-
Beijing, China
- The Military General Hospital of Beijing PLA
-
Shijiazhuang, China
- Bethune International Peace Hospital
-
Tianjin, China
- Tianjin Medical University General Hospital
-
Tianjin, China
- TEDA International Cardiovascular Hospital
-
Tianjing, China
- Tianjing Chest Hospital
-
Xi'an, Shanxi, China
- The First Affiliated Hospital of the Fourth Military Medical University
-
-
Heilongjiang
-
Daqing, Heilongjiang, China
- Daqing General Oilfield Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Jiangsu Province Hospital
-
Nanjing, Jiangsu, China
- Nanjing First Hospital
-
-
Jilin
-
Changchun, Jilin, China
- China Japan Union Hospital of Jilin University
-
-
Liaoning
-
Shenyang, Liaoning, China
- The people Hospital of Liaoning Province
-
-
Shanxi
-
Taiyuan, Shanxi, China
- The Secondary Affiliated Hospital of Shanxi Medical University
-
-
Sichuan
-
Chengdu, Sichuan, China
- West China Hospital of Sichuan University
-
-
Yunnan
-
Kunming, Yunnan, China
- Kunming General Hospital of Chengdu Military Region
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with clinical evidence of asymptomatic or symptomatic ischemic heart disease, stable or unstable angina, old myocardial infarction;
- De novo lesions of native coronary arteries (lesions number ≤2);
- Target lesion located in one or two different vessels. The number of target lesions in one vessel shall be no more than one;
- Target vessel diameter between 2.5 and 4.0 mm by visual estimation. Target lesion length ≤ 32mm by visual estimation, which can be covered by one Combo stent with length 38mm or one Nano stent with length 36mm. It is suggested that the selected stent size should cover at least 2 mm (by visual estimation) of normal tissue on each side of the lesion;
- Target lesion diameter stenosis ≥ 70% by visual estimation;
- Each target lesion is permitted to implant only one stent at most, except bailout stent;
- Patients is eligible for PCI and is an acceptable candidate for CABG;
- Patients with left ventricular ejection fraction (LVEF) ≥40%;
- Patients who can understand the nature of the study, agree to participate and accept angiographic and clinical follow-up, and have provided written informed consent;
Exclusion Criteria:
- Patients with acute myocardial infarction (AMI) within one week;
- Chronic total occlusion lesion (TIMI 0 flow), Left main disease, Ostial lesion, and/or triple-vessel lesion that might require treatment, bifurcation lesions with a side branch diameter >2.5mm or graft lesions;
- Heavily calcified or tortuous lesions which cannot be successfully pre-dilated, and lesions which are not suitable for stent delivery and deployment;
- In-stent restenosis;
- Thrombotic lesion;
- Patients who had received any other stent in the past six months;
- Patients with acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl);
- Patients with cardiogenic shock, acute infection, known bleeding or coagulation disorder, or with a history of active gastrointestinal bleeding, ulcer, cerebral hemorrhage or subarachnoid hemorrhage and stroke within 6 months;
- Patients who are allergic to aspirin, clopidogrel, ticagrelor, ticlopidine, heparin, contrast agent, sirolimus, stainless steel , polymer, or with contraindication to aspirin or clopidogrel or ticagrelor;
- Patients who had previously received murine therapeutic antibodies and exhibited sensitization through the production of HAMA;
- Patients with a life expectancy less than 1year;
- Patients who had participated in another investigational drug or device trial that has not completed the primary endpoint;
- Patient who has received any organ transplant or is on a waiting list for any organ transplant;
- Patient is in the opinion of the investigator, unable to comply with the requirements of the study protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OrbusNeich Combo stent™
The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
|
The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
|
Active Comparator: Nano Polymer-free sirolimus-eluting stent system
The Nano polymer-free sirolimus-eluting stent produced by LePu medical.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-segment late lumen loss (LLL)
Time Frame: 9 months post-procedure
|
In-segment late lumen loss (LLL) refers to within the margins of the stent and 5 mm proximal and 5 mm distal to the stent.
|
9 months post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device-oriented target lesion failure (TLF)
Time Frame: 30 days, 6 months, 12 months and annually up to 5 years
|
The device-oriented target lesion failure (TLF) defined as a composite of cardiac death, target vessel myocardial infarction (MI), and ischemia-driven target lesion revascularization (i-TLR)
|
30 days, 6 months, 12 months and annually up to 5 years
|
Patient-oriented composite endpoint
Time Frame: 30 days, 6 months, 12 months and annually up to 5 years
|
The patient-oriented composite endpoint includes all-cause death, all MIs, or any revascularization
|
30 days, 6 months, 12 months and annually up to 5 years
|
In-stent late lumen loss (LLL)
Time Frame: 9 months post-procedure
|
9 months post-procedure
|
|
In-stent and In-segment binary restenosis (BR)
Time Frame: 9 months post-procedure
|
9 months post-procedure
|
|
In-stent and In-segment minimal lumen diameter (MLD)
Time Frame: 9 months post-procedure
|
9 months post-procedure
|
|
Definite and probable stent thrombosis (ST)
Time Frame: acute (0-24 hours), sub-acute (24 Hours to 30 Days), late (30 Days to 1 year) and very late (1 year to 5 years) period per Academic Research Consortium (ARC) definition criteria
|
Definite and probable stent thrombosis (ST) in acute, sub-acute, late and very late period per Academic Research Consortium (ARC) definition criteria
|
acute (0-24 hours), sub-acute (24 Hours to 30 Days), late (30 Days to 1 year) and very late (1 year to 5 years) period per Academic Research Consortium (ARC) definition criteria
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Tao Ling, M.D., The First Affiliated Hospital of the Fourth Medical University
- Principal Investigator: Xu Bo, M.D, The Secondary Affiliated Hospital of Harbin University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2015
Primary Completion (Actual)
May 27, 2017
Study Completion (Actual)
June 10, 2021
Study Registration Dates
First Submitted
September 1, 2015
First Submitted That Met QC Criteria
September 2, 2015
First Posted (Estimate)
September 4, 2015
Study Record Updates
Last Update Posted (Actual)
September 9, 2021
Last Update Submitted That Met QC Criteria
September 8, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Myocardial Ischemia
- Arteriosclerosis
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- RECOVERY Combo 2015-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Arteriosclerosis
-
Johns Hopkins UniversityNorthwestern UniversityCompletedCoronary Artery Disease | Coronary Arteriosclerosis | Coronary Atherosclerosis | Atherosclerosis, Coronary | Arteriosclerosis, CoronaryUnited States
-
Region Örebro CountyRecruitingCoronary Stenosis | Calcific Coronary ArteriosclerosisSweden
-
Cordis CorporationCompletedCoronary Arteriosclerosis | Angioplasty, Transluminal, Percutaneous Coronary | Peripheral ArteriosclerosisUnited States
-
Luzerner KantonsspitalRecruitingCoronary Artery Disease | Coronary Disease | Coronary Artery Calcification | Stent Restenosis | Calcific Coronary ArteriosclerosisSwitzerland
-
MultiplAI Health LimitedFundación para la Lucha contra las Enfermedades Neurológicas de la InfanciaEnrolling by invitationCoronary Stenosis | Atherosclerotic Plaque | Aortic Calcification | Calcific Coronary Arteriosclerosis | Coronary PlaqueArgentina
-
Hemoteq AGCompletedCoronary Artery Disease | Coronary Arteriosclerosis | Coronary Atherosclerosis | Coronary RestenosisGermany, France
-
Insel Gruppe AG, University Hospital BernRecruitingCoronary Artery Disease | Coronary Arteriosclerosis | Coronary; IschemicSwitzerland
-
Meshalkin Research Institute of Pathology of CirculationCompletedCoronary Artery Disease | Coronary ArteriosclerosesRussian Federation
-
Fatebenefratelli and Ophthalmic HospitalCompletedPercutaneous Coronary Intervention | Angioplasty, Balloon, Coronary | Arteriosclerosis, Coronary | Coronary Angioplasty, Transluminal BalloonItaly
-
Assistance Publique - Hôpitaux de ParisTerminatedCoronary ArteriosclerosisFrance
Clinical Trials on OrbusNeich Combo stent™
-
Prof. Stephen LeeCompletedCoronary Thrombosis | Coronary RestenosisHong Kong
-
OrbusNeichIcahn School of Medicine at Mount SinaiCompleted
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Phillip FreemanOdense University Hospital; Aarhus University Hospital; Biosensors International and other collaboratorsActive, not recruiting
-
Lombard MedicalSuspendedAbdominal Aortic AneurysmsUnited Kingdom, Germany, New Zealand, Spain, Czechia, Italy
-
OrbusNeichGenaeCompletedCoronary Artery Disease | Atherosclerosis | Acute Coronary Syndrome (ACS) | Myocardial Infarction (MI)United Kingdom, Netherlands, Finland, Belgium, Switzerland
-
Silesian School of MedicineMinistry of Science and Higher Education, PolandCompletedCoronary Heart Disease | Acute Coronary SyndromesPoland
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingAbdominal Aortic AneurysmTurkey, Bulgaria, Greece
-
Lombard MedicalCompletedAbdominal Aortic AneurysmsUnited States